AKER AKERS BIOSCIENCE

Akers Biosciences to Attend Hemp Industry Daily Forum in Las Vegas, Nevada

Akers Biosciences to Attend Hemp Industry Daily Forum in Las Vegas, Nevada

Thorofare, New Jersey, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Executive Chairman Christopher Schreiber will attend the “Hemp Industry Daily Forum” on Tuesday, December 10, 2019 as part of MJBizCon Week at the Las Vegas Convention Center in Las Vegas, Nevada. Akers Advisory Board member Bob Hoban is a featured speaker presenting on “International Opportunities” for Hemp operations within the Textiles to Cannabidiol (CBD) space.

Christopher Schreiber added, “MJBizCon is the largest gathering of cannabis related business professionals in the world and a great opportunity for Akers to continue strategic dialogue with potential partners and broaden its relationships in the Hemp and minor cannabinoid space. I look forward to sharing more information on our growth strategy with investors in the near future.”

About Akers Biosciences Inc

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring health related information directly to the patient or clinician in a timely and cost-efficient manner.

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include the Company’s expectation regarding the offering and the exercise of the preferred stock warrants, and the risk that the proposed public offering will not be consummated, the need for additional financing, and any risks detailed from time to time in Akers' reports filed with the Securities and Exchange Commission, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although Akers believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. Akers does not have any obligation to update these forward-looking statements other than as required by law.



Additional information on the company and its products can be found at .

Contact:

Investor Relations:      Hayden IR

                                    Brett Mass, Managing Partner

                                    Phone: (646) 536-7331

                                    Email:

                                   

EN
06/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AKERS BIOSCIENCE

 PRESS RELEASE

Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proo...

Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results Thorofare, New Jersey, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, positive proof of concept results from Animal Studies conducted during a 4 week test of its SARS-CoV-2 vaccine candidate in mice. The test had two primary endpoints, safety and immune response, both of which were met. The candidate was well tolerated and safe in mice that received the i...

 PRESS RELEASE

Akers Biosciences Announces $6.8 Million Registered Direct Offering Pr...

Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Thorofare, New Jersey, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,207,744 shares of the Company’s common stock, at a purchase price of $5.67 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about August 1...

 PRESS RELEASE

Akers Biosciences and Premas Biotech Announce Initiation of Animal Stu...

Akers Biosciences and Premas Biotech Announce Initiation of Animal Studies Company intends to cease focus on screening and testing products business Thorofare, New Jersey, July 07, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, the initiation of animal studies for its SARS-CoV-2 vaccine candidate in India. Premas has successfully completed the manufacturing process for the VLP (virus like particle) vaccine candidate, including three antigens from SARS-...

 PRESS RELEASE

Akers Biosciences Closes $4.8 Million Registered Direct Offering Pric...

Akers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Thorofare, New Jersey, May 18, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the closing of its previously announced registered direct offering of an aggregate of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross pr...

 PRESS RELEASE

Akers Biosciences Announces $4.8 Million Registered Direct Offering P...

Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch